Teva will pay $700 million in cash to acquire Emalex Biosciences, with Emalex shareholders eligible for up to $200 million in commercial milestone payments plus royalties on global net sales of ecopipam. The transaction, funded from Teva’s cash reserves, is expected to close by Q3 2026, subject to regulatory approvals.

Ecopipam is a first-in-class selective dopamine D1 receptor antagonist designed for pediatric Tourette syndrome, holding FDA Orphan Drug and Fast Track designations. Positive Phase 3 data showed a statistically significant improvement on the primary efficacy endpoint (p=0.0084), and Teva plans to submit an NDA in the second half of 2026.

The acquisition aligns with Teva's Pivot to Growth strategy by expanding its late-stage innovative medicines pipeline and leveraging its neuroscience commercial strengths. Teva intends to mitigate near-term margin dilution and remains on track to meet its 2027 financial targets while accelerating patient access to ecopipam.